David F. Bruhn
Boehringer Ingelheim (United States)(US)
Publications by Year
Research Areas
Diabetes Treatment and Management, Diabetes Management and Research, Microbial Natural Products and Biosynthesis, Tuberculosis Research and Epidemiology, Cancer therapeutics and mechanisms
Most-Cited Works
- → Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux(2014)192 cited
- → Patient perspectives on once‐weekly medications for diabetes(2010)127 cited
- → Synthesis, Structure–Activity Relationship Studies, and Antibacterial Evaluation of 4-Chromanones and Chalcones, as Well as Olympicin A and Derivatives(2014)104 cited
- → The economic burden of progressive chronic kidney disease among patients with type 2 diabetes(2013)81 cited
- → Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3-heteroaryl ureas with improved in vitro pharmacokinetic properties(2013)80 cited
- → In vitro and in vivo Evaluation of Synergism between Anti-Tubercular Spectinamides and Non-Classical Tuberculosis Antibiotics(2015)60 cited
- → Structure–Activity Relationships of Spectinamide Antituberculosis Agents: A Dissection of Ribosomal Inhibition and Native Efflux Avoidance Contributions(2016)57 cited
- → Spectinamides are effective partner agents for the treatment of tuberculosis in multiple mouse infection models(2016)50 cited
- → Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK(2011)46 cited
- → Antitubercular nitrofuran isoxazolines with improved pharmacokinetic properties(2012)46 cited